Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Timber Pharmaceuticals Q3 EPS $(0.08) Down From $0.14 YoY, Sales $266.97K Down From $324.52K YoY
Timber Pharmaceuticals (AMEX:TMBR) reported quarterly losses of $(0.08) per share. This is a 157.14 percent decrease over earnings of $0.14 per share from the same period last year. The company reported $266.97 thousand
86 Biggest Movers From Yesterday
Gainers
FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million.
Mid-Afternoon Market Update: Nasdaq Rises 60 Points; Federal Reserve Slows Down Bond Buying
Toward the end of trading Wednesday, the Dow traded down 0.15% to 35,997.82 while the NASDAQ rose 0.38% to 15,709.60. The S&P also rose, gaining 0.13% to 4,636.89.
Mid-Day Market Update: Crude Oil Drops Over 3%; R.R.Donnelley & Sons Shares Jump
Midway through trading Wednesday, the Dow traded down 0.21% to 35,978.38 while the NASDAQ rose 0.08% to 15,662.87. The S&P also fell, dropping 0.10% to 4,625.81.
54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
iRhythm Technologies, Inc. (NASDAQ: IRTC) climbed 38.9% to $106.64. iRhythm Technologies commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule (MPFS) Final Rule.
Timber Pharmaceuticals Q2 EPS $(0.08) Up From $(1.36) YoY
Timber Pharmaceuticals (AMEX:TMBR) reported quarterly losses of $(0.08) per share. This is a 94.12 percent increase over losses of $(1.36) per share from the same period last year.
60 Biggest Movers From Yesterday
Gainers
Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related logistics assets.
Timber Pharma Shares Jump As Mid-Stage Skin Disorder Study With TMB-001 Concludes Enrollment Early
Timber Pharmaceuticals Inc (NYSE: TMBR) has completed enrollment in the Phase 2b CONTROL study evaluating TMB-001, a topical pharmaceutical composition of isotretinoin, for moderate to severe subtypes of congenital ichthyosis (CI).